It was first defined by the Veteran Affairs Lung cancer study Group (VALG) in 1973 and further redefined by the International Association for the Study of Lung Cancer (IASLC) and American Joint Committee on Cancer (AJCC) in 1989 and 2010, respectively.
1 2 Considerable heterogeneity exists pertaining to which definition is used for treating patients in routine practice. As a direct consequence of this, discussions often arise in multidisciplinary tumour board meetings in which different oncologists classify the same patient differently. The subsequent images demonstrate the heterogeneity in subjective classification of patients with SCLC and the role of radiotherapy (RT) in appropriate classification of SCLC.
Figure 2 demonstrates a patient with multiple pulmonary nodules in right upper lobe (cT 3 ) and multiple ipsilateral mediastinal nodes (cN 2 ), Stage IIIA. This case would be classified as LS-SCLC as per VALG and IASLC definitions and possibly extensive stage SCLC (ES-SCLC) as per AJCC definition. Treatment planning images show that if this patient were to be treated with three dimensional conformal radiotherapy (3DCRT), based on total lung minus planning target volume (TL− PTV) receiving 20 Gray (Gy) (V 20 ) and spinal cord maximum dose (D max ) parameters, proceeding with RT would be deemed intolerable and unsafe, respectively, placing this patient into ES-SCLC group. On the contrary, utilising volumetric modulated arc therapy (VMAT) planning satisfies both parameters. Figure 3 demonstrates a patient with a pulmonary mass in left upper lobe (cT 2b ) and multiple contralateral mediastinal nodes (cN 3 ), Stage IIIB. This case would be classified as LS-SCLC as per IASLC and AJCC definitions and ES-SCLC as per VALG definition. Treatment planning images show that utilising 3DCRT would be intolerable as per TL−PTV V 20 parameter, placing this patient in ES-SCLC group. VMAT planning adequately satisfies this parameter. Figure 4 demonstrates a patient with a pulmonary mass in right lower lobe (cT 2b ) with multiple ipsilateral and contralateral mediastinal nodes, ipsilateral supraclavicular fossa nodes and contralateral hilar node (cN 3 Concurrent chemoradiotherapy is the standard of care for LS-SCLC and compared with chemotherapy alone, addition of RT improves 2-year overall survival by 5%-7%. 3 Therefore, emphasis should be placed on determining objectively whether RT can be delivered utilising modern RT techniques in all cases of SCLC.
Contributors IA is the treating junior consultant (radiotherapy), author of the paper, responsible for drafting the manuscript and revising it. He is the guarantor. KSC and SG are the supervising treating consultants (radiotherapy and medical oncology, respectively) and participated in article formulation, editing and oversight. CPB is the physicist, responsible for generating the radiation treatment plan, performing quality assurance of delivered plan and also participated in article editing. demonstrates that the V 20 metric is 34% versus 39% for VMAT and 3DCRT plans, respectively (blue and red horizontal lines, respectively). The constraint for this metric in patients treated definitively with lung carcinomas is V 20 <35% and is associated with <20% risk of developing radiotherapy-induced pneumonitis. 3 Comparison of the PTV and spinal cord histograms demonstrates that despite efforts to protect the spinal cord in the 3DCRT plan (resulting in inferior PTV coverage compared with VMAT), the maximum dose (D max ) of spinal cord is higher (49 Gy for 3DCRT vs 42 Gy for VMAT, blue and red circles, respectively). The constraint for this metric is D max <45 Gy. 3 All other metrics were comparable between both plans. 
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